1Robbins P F, EL-gam il M, Li Y F, et al. Comparison between bacillus calmette gurin and the A60 mycobacterial antigen complex used as cancer preventive immunotherapies[J]. J Exp Med, 1996, 183: 1185.
2Chau L A, Bluestone J A, Madrenas J. Dissociation of intracellular signaling pathways in response to partial agonist ligands of the T cell receptor[J]. Immunol Today, 1998, 19 (9):395.
3Sensi M Farina C, Maccalli C, et al. Imtensified antitumor immunity by a cancer vaccine that produces granulocytemacrophage colony-stimulating factor plus interleukin 4 [J]. J Clin Invest, 1997, 99: 710.
4Alitutti S, Muller S, Dessing M, et al. Different responses are elicited in cytotoxic T lymphocytes by different level of T cell receptor occupancy[J]. J Exp Med, 1996, 183(4): 1917.
5Anzavecchia A. Licence to kill[J]. Nature, 1998, 393 (6684): 413.
6Borst J, Cope A. Turning the immune system on[J]. Immunol Taday, 1999, 20(4): 156.
7Sim B C, Lo D, Gascoigne NRJ. Preferential expression of TCR Va regions in CD4/CD8 subsets: class discrimination or co -receptor recognition[J]. Immunol Today, 1999, 19(6):296.
8Micheletti F, Bazzaro M, Canella A, et al. The lifespan of major histocompatibility complex class I/peptide complexs determines the efficiency of cytotoxic T-lymphocytes responses[J]. Immunology, 1999, 96(3): 411.
9Stayss H J. Immunotherapy with CTLs restrected by nonself MHC[J]. Immunol Today, 1999, 20(4): 180.
10Fields B A. Marinzza R A. Structure and function of the Tcell receptor: insights from X-ray crystallography[J]. Immunol Today, 1996, 17(7): 330.
1Reed J C. The surviving saga goes in vivo [J]. J Clin Invest, 2001, 108(7): 965.
2Tamm I, Wang Y, Sansville E, et al. IAP-family protein Survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases and anticancer drugs [J]. Cancer Res, 1998, 58(12): 5315.
3Robert A O, Paula P S W, Bettina B, et al. Anovel antisense gonucieotide tar geting Survivin expressioninduces apoptosis and sensitizes lung cancer cells tochemotherapy [J]. Cancer Research, 2000, 60(6): 2805.
4Mehdi M, Nathan R W, Jia L, et al. Cancer gene therapy using a Survivin mutant adenovirus [J]. J Clin Invest, 2001, 108(7): 981～990.
5Okada E, Mural Y, Matsui K, et al. Survivin expression in tumor cell nuclei is predictive of a favorable progosis in gasic cancer patients [J]. Cancer Lett, 2001, 163(1): 109.
6Ambrosini G, Adida C, Altieri D C. A novel anti-apoptosis gene, Survivin, expressed in cancer and lymphoma [J]. Nat Med, 1997, 3(8): 917.
7Yoshihik H, Toshihiko T, Akiko M, et al. AnHLA-A24 restricted cytotoxic T lymphocyte epitope of atumor-associated protein, Survivin [J]. Clinical Cancer Research, 2002, 8(6): 1731.
8Islam A, Kageyama H, Takada N, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognosis factors and promotes cell Surviving in human neuroblastomas [J]. Oncogene, 2000, 19(5): 617.
9Abeezar I S, Nigel S, Jane R, et a1. Immunohistochemical detection of the anti-apoptosis protein, Survivin, predicts survival after curative resection of stage Ⅱ colorectal carcinomas [J]. Annals of Surgical Oncology, 2001, 8(5): 305.
10Swana H S, Grossman D, Anthony J N, et al. Antiapoptosis molecule Survivin and recuiTence of bladder cancer [J]. N Engl J Med, 1999, 341(6): 452.
